Gamida Cell Ltd. (GMDA) Prices 12.9M Share Offering at $1.55/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 2/1/2023
- Wall Street down but off session lows after Fed rate hike, trading choppy
- Fed hikes by 0.25% in further downshift on tightening, but sees more hikes ahead
- AMD shares rise after Q4 report that beat expectations for revenue, EPS
- Snap shares plunge 14% following Q4 report, warns of sales drop; analysts mostly bearish
- T-Mobile gains after delivering in 2022, focus turns to massive buyback
- Upstart Holdings (UPST) to lay off 20% of workforce due to current macro headwinds
- Splunk (SPLK) to reduce global workforce by approximately 4%
- Qualtrics (XM) adds to gains as Silver Lake plans bid, analyst sees $20 takeover value
- General Motors (GM) Invests $650M in Lithium Americas (LAC), Enters Supply Agreement
- Silver Lake intends to propose to acquire Qualtrics International (XM) - 13D
- Midday movers: Peloton Interactive, Electronic Arts, Match Group and more
- Snap, EA tumble in premarket; Meta, T-Mobile fall, AMD rises
- After-hours movers: Snap and Match sinks on weak outlooks, AMD gains on EPS
- Midday movers: General Motors, McDonald's, Pfizer and more
- Pfizer, McDonald's fall in premarket, International Paper, UPS jump
Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares
September 28, 2022 12:08 AM EDTBOSTON--(BUSINESS WIRE)-- Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced the pricing of a follow-on public offering of 12,905,000 of its ordinary shares at a public offering price of $1.55 per share for aggregate gross proceeds of $20 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Gamida Cell has granted the underwriters a 30-day option to purchase up to an additional 1,935,750 ordinary shares at the public offering price, less the... More
